Skip to content

Intervention Study of Vitamin D Supplementation to Prevent Cardiovascular Disease

Study of Vitamin D Deficiency on Cardiovascular Disease and the Effect of Vitamin D Supplementation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03339427
Enrollment
100
Registered
2017-11-13
Start date
2014-06-30
Completion date
2015-06-30
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Deficiency

Keywords

vitamin D, cardiovascular, muscle power

Brief summary

This is a 9 months, randomized, single center, open-label, parallel-group study to compare the efficacy and safety parameters of vitamin D supplementation in vitamin D deficiency subjects in China.

Detailed description

This is a 9 months, randomized, single center, open-label, parallel-group study to compare the efficacy and safety parameters of vitamin D supplementation in vitamin D deficiency subjects in China. Eligibility for participation will be determined by medical history, physical examination, and laboratory results obtained during a screening visit. About 300 subjects with vitamin D insufficiency or deficiency will be included in this study. All subjects will be given informed consent before starting any examination and test. The following data of all subject will be collected: liver and kidney function, HbA1c, fasting blood glucose, fasting lipid profile, serum calcium, serum phosphate, parathyroid hormone, 25-hydroxy vitamin D(25OHD), serum procollagen type I N propeptide, serum C-terminal telopeptide of type I collagen, s-CTX and muscle power and balance. After baseline data are collected, eligible subjects will be randomized into each group at a 1:1 ratio (150 for control group and 150 for vitamin D supplementation group, less than 20% drop-off rate is acceptable for this study). The initial vitamin D doses will be based on 25OHD levels at basis, and this dosage may be changed according be the level of 25OHD until the end of this study. All subjects in the control group will be followed every half year. All subjects in the vitamin D group will be followed by visiting clinic, and will be titrated their doses. Dose adjustment should be aimed at achieving the following 25OHD targets: 30ng/ml. If above 25OHD target has not been achieved, vitamin D dose should be adjusted. Clinic visit will be conducted 3 months later to collect information, such as serum calcium, 25OHD and adverse events. Complicated examinations will be repeated again after 9 months treatments for both groups, including physical examination, liver and kidney function, HbA1c, fasting blood glucose, fasting lipid profile, serum calcium, serum phosphate, parathyroid hormone, 25-hydroxy vitamin D(25OHD), serum procollagen type I N propeptide, serum C-terminal telopeptide of type I collagen, s-CTX and muscle power and balance. Data will be collected and analyzed.

Interventions

OTHERcontrol

control group

OTHERvitamin D

different doses of vitamin D supplementation

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Informed consent obtained before any trial-related activities. (Trial- related activities are any procedure that would not have been performed during normal management of the subject.) 2. 25OHD\<30ng/ml

Exclusion criteria

1. Severe systemic disease (including severe heart, liver, kidney and lung diseases, severe infection, mental disorder and connective tissue disease) 2. Primary hyperparathyroidism, other bone disease, malabsorption and other chronic gastrointestinal disease. 3. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures. 4. Use of systemic or inhaled glucocorticoids or other medication known to interfere with bone metabolism. 5. Use of vitamin D related agents in recent 3 months.

Design outcomes

Primary

MeasureTime frameDescription
The efficacy on serum 25(OH)VitD level9 monthsThe change of serum 25(OH)VitD level after vitamin D supplementation
The efficacy on metabolic syndrome9 monthsThe change of metabolic syndrome after vitamin D supplementation

Secondary

MeasureTime frameDescription
The efficacy on bone biomarkers9 monthsThe change of bone biomarkers after vitamin D supplementation
The efficacy on blood pressure9 monthsThe change of blood pressure after vitamin D supplementation
The efficacy on blood lipid9 monthsThe change of blood lipid after vitamin D supplementation
The efficacy on blood glucose9 monthsThe change of blood glucose after vitamin D supplementation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026